Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Charleston, SC
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated:  4/4/2016
Clinical Research Facility
mi
from
Milwaukee, WI
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Status: Enrolling
Updated: 4/4/2016
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Columbia University Medical Center
mi
from
New York, NY
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Bon Secours St. Francis Hospital
mi
from
Greenville, SC
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Bon Secours St. Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated:  4/4/2016
The Mayo Clinic
mi
from
Rochester, MN
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Status: Enrolling
Updated: 4/4/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated:  4/4/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL)
Status: Enrolling
Updated: 4/4/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
PP-Gemcitabine & External Beam Radiation-Sarcomas
A Phase I Study of Preoperative Concomitant Gemcitabine and External-Beam Radiation Therapy and Surgical Resection for Patients With Extremity and Trunk Soft Tissue Sarcomas
Status: Enrolling
Updated:  4/4/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
PP-Gemcitabine & External Beam Radiation-Sarcomas
A Phase I Study of Preoperative Concomitant Gemcitabine and External-Beam Radiation Therapy and Surgical Resection for Patients With Extremity and Trunk Soft Tissue Sarcomas
Status: Enrolling
Updated: 4/4/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors
ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair
Status: Enrolling
Updated:  4/5/2016
Georgetown Cancer Treatment Center
mi
from
Georgetown, KY
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors
ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair
Status: Enrolling
Updated: 4/5/2016
Georgetown Cancer Treatment Center
mi
from
Georgetown, KY
Click here to add this to my saved trials
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors
ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair
Status: Enrolling
Updated:  4/5/2016
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors
ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair
Status: Enrolling
Updated: 4/5/2016
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Semen Analysis After Proton Therapy for Prostate Cancer
Semen Analysis Following Definitive Treatment of Prostate Cancer With Proton Radiation Therapy Alone
Status: Enrolling
Updated:  4/5/2016
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Semen Analysis After Proton Therapy for Prostate Cancer
Semen Analysis Following Definitive Treatment of Prostate Cancer With Proton Radiation Therapy Alone
Status: Enrolling
Updated: 4/5/2016
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/5/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/5/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma
Status: Enrolling
Updated:  4/5/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma
Status: Enrolling
Updated: 4/5/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study
Impact Advanced Recovery® for Radical Cystectomy (RC) Patients
Status: Enrolling
Updated:  4/5/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study
Impact Advanced Recovery® for Radical Cystectomy (RC) Patients
Status: Enrolling
Updated: 4/5/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Energy Balance for Prostate Cancer Survivorship
Energy Balance for Prostate Cancer Survivorship
Status: Enrolling
Updated:  4/5/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Energy Balance for Prostate Cancer Survivorship
Energy Balance for Prostate Cancer Survivorship
Status: Enrolling
Updated: 4/5/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Erlotinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer That Can Be Removed By Surgery
Phase II Study of Erlotinib (Tarceva) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer
Status: Enrolling
Updated:  4/5/2016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Erlotinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer That Can Be Removed By Surgery
Phase II Study of Erlotinib (Tarceva) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer
Status: Enrolling
Updated: 4/5/2016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Status: Enrolling
Updated:  4/5/2016
Indiana University
mi
from
Indianapolis, IN
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Status: Enrolling
Updated: 4/5/2016
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
Status: Enrolling
Updated:  4/6/2016
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
Status: Enrolling
Updated: 4/6/2016
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation
Telephone-Based Genetic Counseling; An Equivalence Trial
Status: Enrolling
Updated:  4/6/2016
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation
Telephone-Based Genetic Counseling; An Equivalence Trial
Status: Enrolling
Updated: 4/6/2016
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation
Telephone-Based Genetic Counseling; An Equivalence Trial
Status: Enrolling
Updated:  4/6/2016
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation
Telephone-Based Genetic Counseling; An Equivalence Trial
Status: Enrolling
Updated: 4/6/2016
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation
Telephone-Based Genetic Counseling; An Equivalence Trial
Status: Enrolling
Updated:  4/6/2016
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation
Telephone-Based Genetic Counseling; An Equivalence Trial
Status: Enrolling
Updated: 4/6/2016
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation
Telephone-Based Genetic Counseling; An Equivalence Trial
Status: Enrolling
Updated:  4/6/2016
Mount Sinai School of Medicine
mi
from
New York, NY
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation
Telephone-Based Genetic Counseling; An Equivalence Trial
Status: Enrolling
Updated: 4/6/2016
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast
Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast (TARGIT-DCIS Trial): Use of Mammography and Breast MRI to Identify Candidates for IORT.
Status: Enrolling
Updated:  4/6/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast
Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast (TARGIT-DCIS Trial): Use of Mammography and Breast MRI to Identify Candidates for IORT.
Status: Enrolling
Updated: 4/6/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC)
Status: Enrolling
Updated:  4/6/2016
Virginia Commonwealth University
mi
from
Richmond, VA
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC)
Status: Enrolling
Updated: 4/6/2016
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated:  4/6/2016
California Cancer Registry
mi
from
Sacramento, CA
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated: 4/6/2016
California Cancer Registry
mi
from
Sacramento, CA
Click here to add this to my saved trials
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated:  4/6/2016
Colorado Central Cancer Registry
mi
from
Denver, CO
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated: 4/6/2016
Colorado Central Cancer Registry
mi
from
Denver, CO
Click here to add this to my saved trials
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated:  4/6/2016
Cancer Data Registry of Idaho
mi
from
Boise, ID
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated: 4/6/2016
Cancer Data Registry of Idaho
mi
from
Boise, ID
Click here to add this to my saved trials
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated:  4/6/2016
University of New Mexico
mi
from
Albuquerque, NM
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated: 4/6/2016
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated:  4/6/2016
Utah Cancer Registry
mi
from
Salt Lake City, UT
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated: 4/6/2016
Utah Cancer Registry
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated:  4/6/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated: 4/6/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated:  4/6/2016
Intermountain Health Care
mi
from
Salt Lake City, UT
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated: 4/6/2016
Intermountain Health Care
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated:  4/6/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)
Impact of Remote Familial Colorectal Cancer Assessment and Counseling
Status: Enrolling
Updated: 4/6/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials
Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials
Status: Enrolling
Updated:  4/6/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials
Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials
Status: Enrolling
Updated: 4/6/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/6/2016
University of Southern California
mi
from
Los Angeles, CA
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/6/2016
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants
Efficacy of Topical Bimatoprost in Promoting Hair Growth in the Region of the Eyebrow and Eyelashes for Post-chemotherapy Patients Versus Normal Patients
Status: Enrolling
Updated:  4/6/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants
Efficacy of Topical Bimatoprost in Promoting Hair Growth in the Region of the Eyebrow and Eyelashes for Post-chemotherapy Patients Versus Normal Patients
Status: Enrolling
Updated: 4/6/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Feasibility Of a Daily Diary Methodology With a Pediatric Cancer Population
The Feasibility Of a Daily Diary Methodology With a Pediatric Cancer Population: A Pilot Study
Status: Enrolling
Updated:  4/6/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
The Feasibility Of a Daily Diary Methodology With a Pediatric Cancer Population
The Feasibility Of a Daily Diary Methodology With a Pediatric Cancer Population: A Pilot Study
Status: Enrolling
Updated: 4/6/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2 Trial of TAK-700 (Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/6/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2 Trial of TAK-700 (Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/6/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors
An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors
An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prostate Cancer Parameters for Patients Receiving Proton Treatment
Longitudinal Study for the Evaluation of Safety and Efficacy Parameters in Prostate Cancer Patients Treated at IU Health Proton Therapy Center (IUHPTC)
Status: Enrolling
Updated:  4/6/2016
Iu Health Proton Therapy Center
mi
from
Bloomington, IN
Prostate Cancer Parameters for Patients Receiving Proton Treatment
Longitudinal Study for the Evaluation of Safety and Efficacy Parameters in Prostate Cancer Patients Treated at IU Health Proton Therapy Center (IUHPTC)
Status: Enrolling
Updated: 4/6/2016
Iu Health Proton Therapy Center
mi
from
Bloomington, IN
Click here to add this to my saved trials
Thermal Signature of Patients Undergoing Radiation Therapy
Phase I Assessment of Thermal Signature of Patients Undergoing Radiation Therapy
Status: Enrolling
Updated:  4/6/2016
U.T.M.D. Anderson Cancer Center
mi
from
Houston, TX
Thermal Signature of Patients Undergoing Radiation Therapy
Phase I Assessment of Thermal Signature of Patients Undergoing Radiation Therapy
Status: Enrolling
Updated: 4/6/2016
U.T.M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of 18F-Fluoro-PEG6-IPQA
A Phase I Study of 18F-Fluoro-PEG6-IPQA as a PET Imaging Agent for Active/Mutant EGFR Expression in Tumors
Status: Enrolling
Updated:  4/7/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of 18F-Fluoro-PEG6-IPQA
A Phase I Study of 18F-Fluoro-PEG6-IPQA as a PET Imaging Agent for Active/Mutant EGFR Expression in Tumors
Status: Enrolling
Updated: 4/7/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Virtual Reality Intervention in Cancer Genetics
Developing Providers' Communication and Counseling Skills in Cancer Genetics Using Virtual Reality
Status: Enrolling
Updated:  4/7/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Virtual Reality Intervention in Cancer Genetics
Developing Providers' Communication and Counseling Skills in Cancer Genetics Using Virtual Reality
Status: Enrolling
Updated: 4/7/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Boston, MA
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
New York, NY
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Portland, OR
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Charleston, SC
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated:  4/7/2016
Clinical Research Facility
mi
from
Dallas, TX
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
Status: Enrolling
Updated: 4/7/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials